Relay Therapeutics, Inc. (NASDAQ: RLAY) is a Healthcare company (Biotechnology) with a market capitalization of $3.6B. The Maz Rating grades it against the other companies in its sector.
Relay Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.47, Relay Therapeutics, Inc. trades at 352.9x sales and 4.4x book value. Over the last twelve months it generated about $10M of revenue and a net loss of $332M. It runs a gross margin of 89.3%, an operating margin of -3094.6% and a net margin of -2837.0%. It shows return on equity of -40.2%, return on invested capital of -37.9% and a free cash flow yield of -5.9%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 14.62. Over the past 52 weeks the share price ranged from $6.25 to $21.27, with a beta of 1.74.
Relay Therapeutics, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 1 Strong Buy and 15 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Relay Therapeutics, Inc. (RLAY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.2% / 30% · Interest income / Revenue 850200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 850200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 850200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 850200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 94.1% / 33.33% · (Cash+Recv) / Total Assets 94.1% / 33.33% · Interest income / Revenue 850200000.0% / 5% | Fail |
No. As of September 2026, Relay Therapeutics, Inc. (RLAY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Relay Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 850200000.0% of each dividend: Relay Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.